NCT05802654

Single Ultra-high Dose Stereotactic Body Radiation Therapy for Early Lung Cancer

Clinical Study of Single Ultra-high Dose Stereotactic Body Radiation Therapy for Early Lung Cancer

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Peking University Third Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The goal of this prospective single-arm phase II study is to study the efficacy and safety of stereotactic body radiotherapy (SBRT) for early lung cancer. The main questions it aims to answer are: How effective is this regimen of SBRT for early lung cancer? How safe is this regimen of SBRT for early lung cancer?

Detailed description

The goal of this prospective single-arm phase II study is to study the efficacy and safety of stereotactic body radiotherapy (SBRT) for early lung cancer. This study intends to enroll 100 participants in 2 years. The participants enrolled will receive single fraction of ultra-high dose stereotactic body radiotherapy (SBRT) (30Gy/1F).

Conditions

• Early Lung Cancer
• Stereotactic Body Radiotherapy

Interventions

Type	Name	Description
RADIATION	SBRT	The participants enrolled will receive single fraction of ultra-high dose SBRT(30Gy/1F).

Timeline

• Start date: 2023-06-01
• Primary completion: 2025-06-01
• Completion: 2028-06-01
• First posted: 2023-04-06
• Last updated: 2023-06-22

Locations

1 site across 1 country: China